Pharmacokinetics of Lanraplenib in Adults With Impaired Renal Function
Status:
Completed
Trial end date:
2018-10-05
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the pharmacokinetics (PK) of lanraplenib
in participants with impaired renal function relative to matched healthy controls.
Participants in this study will be enrolled using an adaptive design that includes up to 3
enrolled cohorts. Based on safety and/or PK data in Cohort 1, participants will be enrolled
in adaptive Cohorts 2 and/or 3.